LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Interaction of Transcription Factors Can Predict DNA Binding

By LabMedica International staff writers
Posted on 13 Feb 2019
Image: A photomicrograph showing the CDX2 transcription factor localized to mitotic chromosomes (Photo courtesy of Dr. David Suter, Ecole Polytechnique Fédérale de Lausanne).
Image: A photomicrograph showing the CDX2 transcription factor localized to mitotic chromosomes (Photo courtesy of Dr. David Suter, Ecole Polytechnique Fédérale de Lausanne).
A team of Swiss stem cell researchers has demonstrated that by observing the binding of transcription factors to mitotic chromosomes it is possible to predict how they will bind non-specifically to DNA.

A transcription factor (TF) (or sequence-specific DNA-binding factor) is a protein that controls the rate of transcription of genetic information from DNA to messenger RNA, by binding to a specific DNA sequence. The function of TFs is to regulate genes in order to make sure that they are expressed in the right cell at the right time and in the right amount throughout the life of the cell and the organism.

TFs regulate gene expression by binding regulatory sequences of target genes. TF ability to occupy specific genomic sites depends on their nuclear concentration, their ability to search the genome, and the chromatin environment of their binding sites. How TFs maximize search efficiency for specific sites is not well understood. To clarify this matter, investigators at Ecole Polytechnique Fédérale de Lausanne (Switzerland) analyzed 501 TFs in mouse embryonic stem cells by determining how they bound to mitotic chromosomes, a property that has been linked to the ability of TFs to associate with DNA in a non-specific manner.

For this study, the investigators combined quantitative measurements of mitotic chromosome binding (MCB), TF mobility measurements by fluorescence recovery after photobleaching, single molecule imaging of DNA binding, and mapping of TF binding and chromatin accessibility.

Results published in the January 30, 2019, online edition of the journal Nature Communications revealed that TFs associating to mitotic chromosomes were enriched in DNA-rich compartments in interphase and displayed slower mobility in interphase and mitosis. MCB correlated with interphase TF properties such as sub-nuclear localization, mobility, and with large differences in TF ability to occupy specific genomic sites. Based on these findings, the investigators proposed that the co-localization of TFs with mitotic chromosomes was a proxy for TF non-specific DNA binding properties, which regulated TF search efficiency for their specific binding sites and thereby their impact on chromatin accessibility.

"Transcription factors differ largely in their ability to scan the genome to find their specific binding sites, and these differences can be predicted by simply looking at how much they bind to mitotic chromosomes," said senior author Dr. David M. Suter, assistant professor of stem cell research at Ecole Polytechnique Fédérale de Lausanne. "Transcription factors that are the most efficient in searching the genome could be able to drive broad changes in gene expression patterns even when expressed at low concentrations, and can therefore be particularly important for cell fate decision processes."

Related Links:
Ecole Polytechnique Fédérale de Lausanne

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more